About Innate Pharma (NASDAQ:IPHYF)
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:IPHYF
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $12.57
- 200 Day Moving Avg: $12.61
- 52 Week Range: $10.72 - $16.55
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $79.68 million
- Price / Sales: N/A
- Book Value: $1.53 per share
- Price / Book: 7.82
- Average Volume: 1,355 shs.
Frequently Asked Questions for Innate Pharma (NASDAQ:IPHYF)
What is Innate Pharma's stock symbol?
Innate Pharma trades on the NASDAQ under the ticker symbol "IPHYF."
Who are some of Innate Pharma's key competitors?
Some companies that are related to Innate Pharma include AA PLC (AATDF), CyberArk Software (CYBR), GoPro (GPRO), Web.com Group (WEB), Atkore International Group (ATKR), G-III Apparel Group, LTD. (GIII), Infinera Corporation (INFN), James River Group Holdings (JRVR), Kearny Financial (KRNY), Uacj Corp (UACJF), SolarEdge Technologies (SEDG), Ascendis Pharma A/S (ASND), Varex Imaging (VREX), FormFactor (FORM), Acorda Therapeutics (ACOR), Sykes Enterprises, Incorporated (SYKE), U S Concrete (USCR) and SPX Corp (SPXC).
How do I buy Innate Pharma stock?
Shares of Innate Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innate Pharma's stock price today?
MarketBeat Community Rating for Innate Pharma (NASDAQ IPHYF)MarketBeat's community ratings are surveys of what our community members think about Innate Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Innate Pharma stock can currently be purchased for approximately $11.96.
Consensus Ratings for Innate Pharma (NASDAQ:IPHYF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Innate Pharma (NASDAQ:IPHYF)
Analysts' Ratings History for Innate Pharma (NASDAQ:IPHYF)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/30/2017||HC Wainwright||Initiated Coverage||Buy -> Buy||Low|
|12/5/2016||Leerink Swann||Reiterated Rating||Buy||N/A|
Earnings History for Innate Pharma (NASDAQ:IPHYF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Innate Pharma (NASDAQ:IPHYF)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Innate Pharma (NASDAQ:IPHYF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Innate Pharma (NASDAQ:IPHYF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Innate Pharma (NASDAQ:IPHYF)
Latest Headlines for Innate Pharma (NASDAQ:IPHYF)
Loading headlines, please wait.
Innate Pharma (IPHYF) Chart for Monday, October, 23, 2017